fenoterol vs Fluticasone propionate/salmeterol (Advair HFA)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

fenoterol

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Partial signal

NCT02177370 · Phase 3 · terminated

This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.

No aligned efficacy figure on record for this race.

Fluticasone propionate/salmeterol (Advair HFA)

Marketed by GlaxoSmithKline

Approved in Asthmacombination (ICS + LABA)
Partial signal

NCT00448435 · Phase 3 · completed

The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.

Reported efficacy

Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)

Result source: NCT00448435

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfenoterolFluticasone propionate/​salmeterol (Advair HFA)
Severe exacerbations, annualised rate—Not reported1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
Trough FEV1, change—Not reported—Not posted · NCT00646620
ACQ-5, change—Not reported—Not posted · NCT00646620
OCS dose reduction—Not reported—Not posted · NCT00646620

Severe exacerbations, annualised rate

fenoterol
—Not reported
Fluticasone propionate/​salmeterol (Advair HFA)
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699

Trough FEV1, change

fenoterol
—Not reported
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

ACQ-5, change

fenoterol
—Not reported
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620

OCS dose reduction

fenoterol
—Not reported
Fluticasone propionate/​salmeterol (Advair HFA)
—Not posted · NCT00646620
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

fenoterol: no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fenoterol: 0 of 4 rows · Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone propionate/​salmeterol (Advair HFA)
Dropout rate
—50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
0%
NCT00449046 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
—50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Serious AEs
0%50/100 mcg/daya
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
0%50/100 mcg/day
NCT00448435 · Phase 3 · Asthma · phase 3
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
—
NCT00449046 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
50/100 mcg/daya
upper respiratory tract inflammation 13.7%
nasopharyngitis 3.9%
stomatitis 3.9%
NCT00448435 · Phase 3 · Asthma · phase 3
show 3 more results
50/100 mcg/day
upper respiratory tract inflammation 34%
gastroenteritis 14%
nasopharyngitis 14%
NCT00448435 · Phase 3 · Asthma · phase 3
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
asthma 20%
bronchitis 20%
laryngopharyngitis 20%
NCT00449046 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone propionate/salmeterol (Advair HFA)

Morning PEF Change L/Min 14.3 vs 17.1 SLM + FP L50/100 mcg/day
absolute change · L
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 5.38% (n=48) vs 6.73% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 5.01% (n=48) vs 6.46% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 16.3 vs 15.8 SLM + FP L/min50/100 mcg/day
absolute change · L/min
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation 0.06% (n=48) vs -0.08% (n=48) SLM + FP50/100 mcg/day
absolute change · percentage points
NCT00448435 · Phase 3 · Asthma · phase 3
Symptom-Free Nights and 91.7% (n=48) vs 81.3% (n=48) SLM + FP @ 4wk50/100 mcg/day
absolute value · percentage points
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Rescue Medication-Free Nights 93.8% (n=48) vs 87.5% (n=48) SLM + FP @ 4wk50/100 mcg/day
responder rate · % of participants
After 4 Weeks of Treatment
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Change L/Min 3 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Predicted 1.46% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Percent Personal Best 1.29% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Evening PEF Change L/Min 2.7 L/min @ 30wk50/100 mcg/day
absolute change · L/min
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3
Morning PEF Circadian Variation -0.37% (n=50) @ 30wk50/100 mcg/day
absolute change · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00448435 · Phase 3 · Asthma · phase 3

+ 12 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fenoterol's landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape